Palmer: The Changing Landscape of Early-Phase Cell and Immunotherapy Clinical Trials in Oncology

Joycelynne Palmer: “The Changing Landscape of Early-Phase Cell and Immunotherapy Clinical Trials in Oncology”

The early-phase trial design landscape in oncology continues to evolve in direct response to advances in our understanding of cancer biology and the development of cell and immunotherapy. Given the underlying complexity and cost associated with conducting such studies, in recent years, Biostatisticians have worked to develop more seamless and efficient approaches to the evaluation of these novel therapeutics. Dr. Palmer will provide a brief overview of the changing trial design landscape and highlight the key contributions made by Biostatisticians in this space.

Dr. Palmer is a Biostatistician with a background in the biological sciences, training in systems analysis, biostatistics and epidemiology, and a 25+ year history of collaboration in biomedical research spanning basic science, translational, clinical, and epidemiological projects. In her role as the Biostatistics Core Director for the Hematologic Malignancies Research Institute (HMRI) at City of Hope, she provides scientific oversight and statistical support (design, monitoring, analysis, and reporting) for this Core, the Cellular Immunotherapy Center, and all hematology related programs. Dr. Palmer’s research interests and effort support pre-clinical and clinical studies concerning the major obstacles to disease control/cure of hematologic malignancies and successful hematopoietic stem cell transplantation (HSCT).